Skip to main content
. Author manuscript; available in PMC: 2023 Feb 3.
Published in final edited form as: Breast Cancer Res Treat. 2022 Feb 3;192(1):153–161. doi: 10.1007/s10549-021-06475-2

Figure 3. SF-36 Vitality scale score by treatment group and time point.

Figure 3.

Adjusted least-square mean scores for all timepoints after baseline are obtained from mixed model for repeated measures analysis of the score.

AC, doxorubicin and cyclophosphamide; FEC-100, 5-fluorouracil, epirubicin and cyclophosphamide Footnote: *statistically significant differences observed: 6 months: FEC-100:57.06; AC:59.97, difference=−2.91, 95%CI=(− 4.89,−0.93), P value=0.004.